uniQure N.V. - Ordinary Shares (QURE): Price and Financial Metrics
uniQure N.V. - Ordinary Shares (QURE)
Today's Latest Price: $47.45 USD
2.41 (5.35%)
Updated Mar 31 6:55pm
Add QURE to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
QURE Stock Summary
- uniQure NV's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 8.89% of US listed stocks.
- QURE's price/sales ratio is 264.64; that's higher than the P/S ratio of 99% of US stocks.
- Revenue growth over the past 12 months for uniQure NV comes in at -35.48%, a number that bests only 5.31% of the US stocks we're tracking.
- Stocks that are quantitatively similar to QURE, based on their financial statements, market capitalization, and price volatility, are CNCE, CRNX, SNDX, INO, and FATE.
- QURE's SEC filings can be seen here. And to visit uniQure NV's official web site, go to www.uniqure.com.
QURE Daily Price Range
QURE 52-Week Price Range
QURE Stock Price Chart More Charts
QURE Price/Volume Stats
| Current price | $47.45 | 52-week high | $82.49 |
| Prev. close | $45.04 | 52-week low | $36.20 |
| Day low | $44.03 | Volume | 323,600 |
| Day high | $47.69 | Avg. volume | 464,287 |
| 50-day MA | $54.32 | Dividend yield | N/A |
| 200-day MA | $57.73 | Market Cap | 2.10B |
uniQure N.V. - Ordinary Shares (QURE) Company Bio
uniQure is a biopharmaceutical company, developing adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company was founded in 1998 and is based in Amsterdam, the Netherlands.
Top Stories View All
Best & Worst Performing Stock Industries for March 31, 2020
Best & Worst Performing Small Cap Stocks for March 31, 2020
Best & Worst Performing Mid Cap Stocks for March 31, 2020
Best & Worst Performing Large Cap Stocks for March 31, 2020
Best & Worst Performing Mega Cap Stocks for March 31, 2020
View All Top Stories
Loading social stream, please wait...